截至9月30日，英诺特股东户数8037.00，较上期增加10.57%；人均流通股8627股，较上期减少8.86%。 2025年1月-9月，英诺特实现营业收入3.30亿元，同比减少36.56%；归母净利润1.31亿元，同比减少 46.37%。 分红方面，英诺特A股上市后累计派现1.52亿元。 机构持仓方面，截止2025年9月30日，英诺特十大流通股东中，医疗器械ETF（159883）位居第九大流 通股东，持股49.80万股，为新进股东。 1月26日，英诺特涨0.22%，成交额1.30亿元。两融数据显示，当日英诺特获融资买入额1661.74万元， 融资偿还1311.01万元，融资净买入350.73万元。截至1月26日，英诺特融资融券余额合计2.46亿元。 融资方面，英诺特当日融资买入1661.74万元。当前融资余额2.46亿元，占流通市值的9.94%，融资余额 超过近一年70%分位水平，处于较高位。 融券方面，英诺特1月26日融券偿还1200.00股，融券卖出1000.00股，按当日收盘价计算，卖出金额3.56 万元；融券余量8100.00股，融券余额28.87万元，超过近一年80%分位水平，处于高位。 资料显示 ...

Core Viewpoint - The stock of Meihao Medical (301363) experienced a decline of 5.46% on January 26, 2026, closing at 32.18 yuan, with significant capital outflows from major and retail investors [1]. Group 1: Stock Performance and Trading Data - On January 26, 2026, the stock had a turnover rate of 4.83%, with a trading volume of 180,300 hands and a total transaction amount of 596 million yuan [1]. - The net outflow of main funds was 74.07 million yuan, accounting for 12.43% of the total transaction amount, while retail investors saw a net inflow of 92.38 million yuan, representing 15.5% of the total [1]. Group 2: Financing and Margin Trading Information - On the same day, the financing buy amounted to 48.69 million yuan, while financing repayment was 58.85 million yuan, resulting in a net repayment of 10.16 million yuan [2]. - The margin trading balance stood at 321 million yuan, with a short selling of 2,400 shares and a remaining short position of 50,800 shares [2]. Group 3: Financial Performance - For the first three quarters of 2025, Meihao Medical reported a main revenue of 1.194 billion yuan, a year-on-year increase of 3.28%, while the net profit attributable to shareholders decreased by 19.25% to 208 million yuan [2]. - In Q3 2025, the company achieved a single-quarter main revenue of 462 million yuan, up 2.56% year-on-year, and a net profit of 93.90 million yuan, reflecting a year-on-year increase of 5.89% [2]. - The company reported a debt ratio of 11.43% and a gross profit margin of 39.34% [2]. Group 4: Analyst Ratings - In the last 90 days, seven institutions have given a buy rating for Meihao Medical, with an average target price of 24.57 yuan [3].

Core Viewpoint - The pharmaceutical sector is experiencing significant capital inflow, driven by the emergence of Nipah virus cases in India, which has heightened interest in vaccines and innovative drugs, alongside the continuous expansion of Chinese pharmaceutical companies in overseas markets [1] Group 1: Market Dynamics - On January 26, the pharmaceutical sector saw a notable increase in capital inflow, with market sentiment becoming more active due to multiple factors, including marginal improvements in industry fundamentals and supportive policies [1] - The emergence of overseas pandemic events, such as Nipah virus infections, has reignited market focus on vaccines, antiviral drugs, and public health defense systems, reinforcing long-term investment confidence in the pharmaceutical sector, particularly in innovative drugs, vaccines, and diagnostics [1] Group 2: Structural Opportunities - Recent institutional insights indicate that structural opportunities within the pharmaceutical sector are becoming clearer, with the strong momentum of innovative drugs continuing to be a core driver of the sector [1] - By January 2026, several companies, including Yilian Biotech and Rongchang Biotech, have achieved licensing agreements, validating the global competitiveness of Chinese innovative drugs, especially in cutting-edge technology areas like ADC, bispecific antibodies, and small nucleic acids [1] Group 3: Sector Developments - Progress in specific subfields is enhancing confidence in the sector, with small nucleic acid drugs showing positive clinical data in chronic hepatitis B and metabolic diseases, attracting accelerated investments from leading domestic and international companies [2] - Breakthroughs in oral immunomodulatory drugs targeting new pathways provide new treatment options for difficult diseases such as psoriasis and ulcerative colitis, warranting ongoing monitoring of related domestic companies' clinical advancements [2] - The GLP-1 class products maintain high demand in the weight loss and diabetes markets, with a gradually forming domestic pricing system and rapid overseas market expansion opening up further growth opportunities [2] Group 4: Investment Strategies - Institutions suggest investors focus on the following main lines for pharmaceutical sector investments: - Concentrate on cutting-edge areas of innovative drugs, particularly in the accelerating overseas expansion of bispecific antibodies, ADC, and small nucleic acids, such as YK Pharma and Sunlight Novo [3] - Capitalize on innovative breakthroughs in tumor therapeutic vaccines [3] - Invest in the CXO and research service industry chain that supports innovative research and development, such as Yinos and Zhaoyan New Drug [3] - Pay attention to traditional Chinese medicine and pharmacy sectors with overseas potential or high dividend defensive attributes, such as Zoli Pharmaceutical, Dong'e Ejiao, and Yifeng Pharmacy [3]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Views - The pharmaceutical sector underperformed the overall market, with a 0.39% decline in the biopharmaceutical sector compared to a 1.17% increase in the overall A-share market [32] - The TTM price-to-earnings ratio for the pharmaceutical sector is 38.51x, which is at the 84.35 percentile of the historical valuation over the past five years [32][37] Summary by Sections Market Performance - The overall A-share market increased by 1.17%, while the Shanghai and Shenzhen 300 index decreased by 0.62%. The biopharmaceutical sector saw a decline of 0.39% [32] - Among sub-sectors, chemical pharmaceuticals fell by 1.11%, while medical services dropped by 2.17%. Conversely, medical commercial and traditional Chinese medicine sectors saw increases of 4.26% and 0.89%, respectively [32] Fund Holdings Analysis - As of Q4 2025, the net asset value of pharmaceutical funds reached 358.4 billion, a decrease of 9.0% from the previous quarter [11] - The proportion of pharmaceutical holdings in all funds was 7.97%, down by 1.71 percentage points [16] - The largest sub-sectors by holdings were chemical preparations (37.5%) and other biological products (20.8%) [19] Key Company Earnings Forecasts and Investment Ratings - Major companies such as Mindray Medical (237 billion market cap, outperform rating), WuXi AppTec (293.6 billion market cap, outperform rating), and Aier Eye Hospital (105.4 billion market cap, outperform rating) are highlighted for their strong earnings forecasts [4] - The report lists several companies with outperform ratings, including New Industry, Huatai Medical, and others, with projected earnings growth over the next few years [4] Investment Strategy - The report emphasizes the importance of the CXO sector and recommends focusing on investment opportunities within this area due to its competitive advantages [41] - It also suggests continued recommendations for innovative drugs and the associated industry chain, with a specific investment portfolio for January 2026 including companies like Mindray Medical and WuXi AppTec [42][43]

Core Insights - Chengdu is leveraging its unique cultural and tourism resources to attract global tourists and enhance the purchasing experience for overseas visitors, focusing on the internationalization of local brands [1][3] Group 1: Government Initiatives - The Chengdu Municipal Bureau of Commerce organized the "2026 Chengdu Urban Circle Tax-Free Product Supply and Demand Matching Conference" to create a bridge between production and sales, aiming for resource complementarity [1] - The government is developing a product matrix for tax-free goods that includes local specialties such as panda cultural products, Shu embroidery, and Sichuan tea and liquor, while also establishing a demand-driven analysis mechanism [3] Group 2: Business Opportunities - Companies like Sichuan Qianli Beiyikang Medical Technology Co., Ltd. are entering tax-free stores to enhance visibility and access stable high-end sales channels, which accelerates their overseas brand establishment [4] - Chengdu Yaohua Food Co., Ltd. views entry into tax-free stores as a strategic move to reach high-net-worth tourists, improve brand exposure, and reduce barriers to cooperation in tax-free channels [5] Group 3: Market Trends - The main categories for tax refunds include clothing, bags, shoes, jewelry, and electronics, indicating a strong market for local cultural brands that resonate with tourists [5] - As of November 30, 2025, Chengdu has over 600 tax-free stores, with more than 180 offering "buy and refund" services, enhancing the shopping experience for global travelers [5]

活动现场，"蓉品蓉企出川出海综合服务平台"正式首发上线。据悉，该平台将聚焦企业出川出海核心需 求，在服务业态上实现货贸、服贸等全覆盖，在服务内容上实现"政务+行业+市场"全贯通，在服务场 景上构建"线上智能平台+线下实体空间"双场景服务模式，通过政策集成辅导、出海选品展示、全球市 场拓展、仓储物流共享、跨境金融支持等九大专项服务帮助企业降低出海门槛，推动成都都市圈及全川 企业高效"走出去"。 四川识南酒业有限公司董事长鄢源东来之前就对到会的企业深入了解了一番，并进行了重点标记，"会 议结束，我们计划和原料、销售、供应链相关的企业一一沟通交流，探讨合作的可能性。"他向记者透 露。 为进一步丰富免退税商店的商品品类，促进蓉企蓉品出川出海，成都市商务局会同市级相关部门及各区 （市）县商务主管部门，同期举办"2026成都都市圈免退税产品供需对接会"。在市商务局相关负责人看 来，在免退税商店推广国货"潮品"和特色产品，能有效提升免税店吸引力，满足游客多元化需求，提升 购物体验，进一步扩大入境消费。 转自：成都日报锦观 四川千里倍益康医疗科技股份有限公司作为四川省第二家A股上市的医疗器械企业，专注于智能康复设 备的研发、 ...

北京万东医疗科技股份有限公司 第十届董事会第十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 北京万东医疗科技股份有限公司（以下简称"公司"）第十届董事会第十三次会议于2026年1月26日以通 讯表决方式召开。本次会议的会议通知及相关资料于2026年1月21日以电子邮件的方式向全体董事发 出。会议应到董事8人，实到8人，公司高管人员列席会议。本次会议的召开符合《公司法》和《公司章 程》的规定，所作决议合法有效。 依据《公司章程》规定，会议由董事共同推举王建国先生主持，形成如下决议： 一、审议通过《关于选举董事长的议案》。 选举王建国先生为公司第十届董事会董事长。具体内容详见公司披露于上海证券交易所网站的（2026- 008）《万东医疗关于董事长离任暨选举董事长的公告》。 本议案表决结果：同意8票，反对0票，弃权0票。 证券代码：600055 证券简称：万东医疗 公告编号：2026-007 二、审议通过《关于调整第十届董事会部分专门委员会成员的议案》。 为完善公司治理结构，保证董事会专门委员会能够顺利高效开展工 ...

◎记者 赵明超 2025年春，创新药板块"忽如一夜春风来"，各家药企BD交易"千树万树梨花开"，一场轰轰烈烈的创新 药行情随之展开，在三季度上演"秋收"行情，但随后又迎来震荡调整，处于"冬藏"状态。 走过2025年的"秋收冬藏"行情之后，2026年的创新药行情如何演绎？整个医药板块有哪些投资机会？上 海证券报记者邀请平安医药精选股票基金经理周思聪、长城医药产业基金经理梁福睿、融通健康产业基 金经理万民远，就上述问题分享看法。 未来向好 创新药重估进行时 上海证券报：站在当前时点，如何看创新药行业2026年的投资机会？ 周思聪：2025年，创新药全球BD交易爆发式增长，验证了中国国内研发的质量，市场对创新药企业进 行重估，创新药板块强劲反弹，但目前基本还没有演绎创新药行业的业绩主线。 2026年，市场叙事将从广泛的估值重估转向基本面落地，市场将更加严苛地审视公司的每一个临床数 据、每一份销售财报和每一次BD交易的质量。能否持续产出有价值的创新成果，以及能否将这些成果 高效地转化为商业收入，是决定未来公司价值的核心。未来的赢家将是那些能够将其科学创新成功地转 化为商业成果的公司。 梁福睿：2025年二、三季度创新 ...

截至2026年1月26日收盘，拱东医疗(605369)报收于19.8元，上涨0.76%，换手率1.23%，成交量2.7万 手，成交额5303.08万元。 当日关注点 交易信息汇总 资金流向 公司公告汇总 拱东医疗：关于变更签字会计师的公告 浙江拱东医疗器械股份有限公司原聘任天健会计师事务所宁一锋和郭森浩为2025年度签字注册会计师， 因事务所内部工作安排调整，现变更为宁一锋和杨国庆。杨国庆自2015年成为中国注册会计师，近三年 签署或复核万胜智能、长城科技等上市公司审计报告，具备相应专业能力和独立性，最近三年未因执业 行为受到处罚。此次变更不会对公司2025年度财务报表及内部控制审计工作产生不利影响。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：1月26日主力资金净流出40.2万元，散户资金净流入550.86万元，占总成交额 10.39%。 来自公司公告汇总：拱东医疗变更2025年度签字会计师，新增杨国庆为签字注册会计师，具备专 业能力且近三年无处罚记录。 1月26日主力资金净流出40.2万元，占总成交额0.7 ...

截至2026年1月26日收盘，大博医疗(002901)报收于48.3元，下跌3.69%，换手率1.03%，成交量2.98万 手，成交额1.45亿元。 2025年度业绩预告 大博医疗科技股份有限公司发布2025年度业绩预告，预计归属于上市公司股东的净利润为58,000万元至 61,000万元，同比增长62.55%至70.96%；扣除非经常性损益后的净利润为45,500万元至48,500万元，同 比增长59.42%至69.93%。基本每股收益为1.43元/股至1.50元/股。业绩增长主要得益于公司聚焦主业、 推进产品创新和国际化战略。该数据为财务部门初步测算结果，未经审计，最终以2025年年度报告为 准。 业绩预告 大博医疗发布业绩预告，预计2025年全年归属净利润盈利5.8亿元至6.1亿元。大博医疗发布业绩预告， 预计2025年全年扣非后净利润盈利4.55亿元至4.85亿元。大博医疗发布业绩预告，预计2025年全年每股 收益盈利1.43元至1.5元。 公司公告汇总 当日关注点 交易信息汇总 资金流向 1月26日主力资金净流出181.7万元；游资资金净流入1052.12万元；散户资金净流出870.43万元。 业绩 ...